Advisor Group’s Celldex Therapeutics CLDX Stock Holding History

Advisor Group’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	$1K	Hold	291	–	–	﹤0.01%	5111
2019 Q3	$1K	Hold	291	–	–	﹤0.01%	5087
2019 Q2	$1K	Hold	291	–	–	﹤0.01%	5079
2019 Q1	$1K	Sell	291 -3	-1%	-$16	﹤0.01%	5038
2018 Q4	$1K	Sell	294 -747	-72%	-$3.67K	﹤0.01%	4939
2018 Q3	$7K	Hold	1,041	–	–	﹤0.01%	4441
2018 Q2	$8K	Buy	1,041 +495	+91%	+$6.62K	﹤0.01%	4172
2018 Q1	$19K	Buy	546 +7	+1%	+$271	﹤0.01%	3704
2017 Q4	$24K	Sell	539 -838	-61%	-$35.9K	﹤0.01%	3587
2017 Q3	$59K	Buy	1,377 +30	+2%	+$1.13K	﹤0.01%	2821
2017 Q2	$50K	Sell	1,347 -343	-20%	-$15.2K	﹤0.01%	2853
2017 Q1	$91K	Buy	1,690 +1,132	+203%	+$58.9K	﹤0.01%	2229
2016 Q4	$30K	Buy	558 +344	+161%	+$19.6K	﹤0.01%	2967
2016 Q3	$13K	Sell	214 -4	-2%	-$249	﹤0.01%	3398
2016 Q2	$13K	Buy	+218	New	+$13.8K	﹤0.01%	3320

Other funds holding CLDX

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CAM

Cresset Asset Management Chicago, Illinois $27.6B AUM 31.92% 1-Year Est. Return

TCMG

TSP Capital Management Group Summit, New Jersey $418M AUM 68.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

Advisor Group's CLDX Position: Q4 2019 in Review

Advisor Group held its Celldex Therapeutics (CLDX) position steady in Q4 2019 at 291 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #5111.

Advisor Group first reported a position in CLDX in Q2 2016 and has held it in 15 quarters since. The position peaked at $91K in Q1 2017. 48 funds tracked by Wall St. Rank hold CLDX as of Q4 2019.

Advisor Group held 291 shares of Celldex Therapeutics worth $1K as of Q4 2019.
Advisor Group left its Celldex Therapeutics share count unchanged in Q4 2019.
Celldex Therapeutics made up ﹤0.01% of Advisor Group's portfolio in Q4 2019, its #5111 holding.
Advisor Group first reported a position in Celldex Therapeutics in Q2 2016 and has held it in 15 quarters since.
Advisor Group's Celldex Therapeutics position peaked at $91K in Q1 2017.
48 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q4 2019.

Based on Advisor Group's 13F filing for Q4 2019, filed 12 Feb 2020.